Annals of Surgical Oncology

, Volume 24, Issue 12, pp 3771–3779 | Cite as

FBXO50 Enhances the Malignant Behavior of Gastric Cancer Cells

  • Takashi Miwa
  • Mitsuro Kanda
  • Haruyoshi Tanaka
  • Chie Tanaka
  • Daisuke Kobayashi
  • Shinichi Umeda
  • Naoki Iwata
  • Masamichi Hayashi
  • Suguru Yamada
  • Tsutomu Fujii
  • Michitaka Fujiwara
  • Yasuhiro Kodera
Translational Research and Biomarkers



Challenges to our understanding the molecular mechanisms of the progression of gastric cancer (GC) must be overcome to facilitate the identification of novel biomarkers and therapeutic targets. In this article, we analyzed the expression of the gene encoding F-box-only 50 (FBXO50) and determined whether it contributes to the malignant phenotype of GC.


FBXO50 messenger RNA (mRNA) levels and copy numbers of the FBXO50 locus were determined in 10 GC cell lines and a nontumorigenic epithelial cell line. Polymerase chain reaction array analysis was performed to identify genes coordinately expressed with FBXO50. The effects of inhibiting FBXO50 on GC cell proliferation, adhesion, invasiveness, and migration were evaluated using a small interfering RNA targeted to FBXO50 mRNA. To evaluate the clinical significance of FBXO50 expression, we determined the levels of FBXO50 mRNA in tissues acquired from 200 patients with GC.


The levels of FBXO50 mRNA were increased in five GC cell lines and positively correlated with those of ITGA5, ITGB1, MMP2, MSN, COL5A2, GNG11, and WNT5A. Copy number gain of the FBXO50 locus was detected in four GC cell lines. Inhibition of FBXO50 expression significantly decreased the proliferation, adhesion, migration, and invasiveness of GC cell lines. In clinical samples, high FBXO50 expression correlated with increased pT4, invasive growth, lymph node metastasis, and positive peritoneal lavage cytology. Patients with high FBXO50 expression had a significantly higher prevalence of recurrence after curative gastrectomy and were more likely to experience shorter overall survival.


FBXO50 may represent a biomarker for GC phenotypes and as a target for therapy.




Supplementary material

10434_2017_5882_MOESM1_ESM.doc (42 kb)
Supplementary material 1 (DOC 42 kb)
10434_2017_5882_MOESM2_ESM.tif (6.2 mb)
Supplementary material 2 (TIFF 6360 kb) FBXO50 mRNA expression levels in clinical tissues


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMedGoogle Scholar
  5. 5.
    Kanda M, Shimizu D, Tanaka H, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Ann Surg. 2016.Google Scholar
  6. 6.
    Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene. 2005;24:3448–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Yu Y, Sun L, Ren N, Li Y, Rong L, Zhao G. Down-expression of F box only protein 8 correlates with tumor grade and poor prognosis in human glioma. Int J Clin Exp Pathol. 2014;7:8071–76.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Zhang C, Li X, Adelmant G, et al. Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21. Proc Natl Acad Sci USA. 2015;112:15372–77.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cepeda D, Ng HF, Sharifi HR, et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 2013;5:1067–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kanda M, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 2016;139:2290–98.CrossRefPubMedGoogle Scholar
  12. 12.
    Kallio H, Tolvanen M, Janis J, et al. Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins. PLoS One. 2011;6:e27152.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kanda M, Shimizu D, Fujii T, et al. Neurotrophin receptor-interacting melanoma antigen-encoding gene homolog is associated with malignant phenotype of gastric cancer. Ann Surg Oncol. 2016;23 Suppl 4:532–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Kanda M, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 2016;19:255–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka H, Kanda M, Shimizu D, et al. FAM46C serves as a predictor of hepatic recurrence in patients with resectable gastric cancer. Ann Surg Oncol. 2016.Google Scholar
  18. 18.
    Kanda M, Shimizu D, Fujii T, et al. Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. Int J Oncol. 2016;49:1195–202.PubMedGoogle Scholar
  19. 19.
    Oya H, Kanda M, Sugimoto H, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590–600.CrossRefPubMedGoogle Scholar
  20. 20.
    Chiorazzi M, Rui L, Yang Y, et al. Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proc Natl Acad Sci USA. 2013;110:3943–48.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tian X, Dai S, Sun J, et al. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression. Oncotarget. 2015;6:22767–75.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    umimoto K, Akiyoshi S, Ueo H, et al. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Investig. 2015;125:621–35.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kuuselo R, Simon R, Karhu R, et al. 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer. 2010;49:569–75.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Smith DH, Christensen IJ, Jensen NF, et al. An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. BMC Cancer. 2013;13:489.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Orsetti B, Selves J, Bascoul-Mollevi C, et al. Impact of chromosomal instability on colorectal cancer progression and outcome. BMC Cancer. 2014;14:121.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wu Q, Hou X, Xia J, et al. Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev. 2013;39:640–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bae GY, Choi SJ, Lee JS, et al. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget. 2013;4:2512–22.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Prasad CP, Chaurasiya SK, Guilmain W, Andersson T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2016;35:144.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Takashi Miwa
    • 1
  • Mitsuro Kanda
    • 1
  • Haruyoshi Tanaka
    • 1
  • Chie Tanaka
    • 1
  • Daisuke Kobayashi
    • 1
  • Shinichi Umeda
    • 1
  • Naoki Iwata
    • 1
  • Masamichi Hayashi
    • 1
  • Suguru Yamada
    • 1
  • Tsutomu Fujii
    • 1
  • Michitaka Fujiwara
    • 1
  • Yasuhiro Kodera
    • 1
  1. 1.Department of Gastroenterological Surgery (Surgery II)Nagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations